SQUAWK/NEWS
Account
Theme
Menu
Site Search

Search market news

Find public news by keyword, exact ticker, category and date.

News by ticker →AAPL newsSPY newsEarnings
News Feed

2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.

News 2026-10-16 15:49 UTC

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG — Unresponsive NMIBC With CIS, With or Without Papillary Tumors

For best results when printing this announcement, please click on link below: ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA(® )Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors Peer-reviewed publication r

IBRX.O
News 2026-10-16 15:49 UTC

ImmunityBio Reports Long-Term ANKTIVA Data in Bladder Cancer Study

ImmunityBio said long-term data from its Phase 2/3 QUILT-3.032 study (N=100) were published in the Journal of Urology. The study reported 84% cystectomy avoidance at three years and complete responses beyond 53 months among patients receiving ANKTIVA plus BCG for BCG-unresponsive NMIBC with CIS, with or without papilla

IBRX